Sirt6 regulates the Notch signaling pathway and mediates autophagy and regulates podocyte damage in diabetic nephropathy., PMID:39754634
The association between NADPH oxidase (NOX) polymorphisms with immunohistochemistry and survival in diffuse large B cell lymphoma patients., PMID:39774928
Bcl-2 and galectin-3 expression is associated with recurrence of ameloblastoma., PMID:39802810
Therapeutic potential of brentuximab vedotin in breast cancer and lymphoma via targeted apoptosis and gene regulation., PMID:39805861
Phosphorylation of Bok at Ser-8 blocks its ability to suppress IP3R-mediated calcium mobilization., PMID:39810210
Targeting refractory diffuse large B cell lymphoma by CAR-WEE1 T-cells: In vitro evaluation., PMID:39820427
The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics., PMID:39827471
Assessment of the level of apoptosis in differentiated pseudo-neuronal cells derived from neural stem cells under the influence of various inducers., PMID:39850017
Interaction of zinc oxide nanoparticles and nanorods with immunoglobulin G and underlying effects on MCF-7 breast cancer cells., PMID:39938843
Treatment of Relapsed/Refractory AML-Novel Treatment Options Including Immunotherapy., PMID:39960017
Basal Cell Carcinoma: A Digital Study of Immunohistochemical BCL2, P53 and CD138 Expression in Low- and High-Risk Types., PMID:40007456
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL., PMID:40009494
Increased anti-apoptotic (Bcl-2+) and decreased proliferative (Ki-67+) cell fractions during the different maturation stages of bone marrow cell populations in MDS and AML: The potential diagnostic impact of the Bcl-2:Ki-67 ratio., PMID:40051252
Deciphering the IgG Idiotype Network Through Proteomic Analysis of Potential Targets in SARS-CoV-2-Induced Immune Responses., PMID:40077865
Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy., PMID:40084099
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy., PMID:40113751
Diffuse large B-cell lymphoma with partial low Ki67 proliferation index., PMID:40138154
Potential role of liver-resident CD3+ macrophages in HBV clearance in a mouse hepatitis B model., PMID:40143948
Zanubrutinib plus R-CHOP improves the treatment effect of newly diagnosed diffuse large B cell lymphoma with double expression of MYC and BCL-2., PMID:40145086
[Update on marginal zone lymphoma classification, diagnosis and treatment in 2024]., PMID:40157832
Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukaemia., PMID:40209064
The Protective Effects of MSC-Derived Exosomes Against Chemotherapy-Induced Parotid Gland Cytotoxicity., PMID:40223864
Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report., PMID:40230856
Long term follow-up of MRD guided treatment of Ibrutinib plus Venetoclax for Relapsed CLL: phase 2 VISION/HO141 trial., PMID:40249856
Evaluating Apoptotic Gene Efficiency for CHO Culture Performance Using Targeted Integration., PMID:40268279
Roles of GDF9 and BMP15 in equine follicular development: in vivo content and in vitro effects of IGF1 and cortisol on granulosa cells., PMID:40289073
In Silico Molecular Docking of 2-Hydroxyanthraquinone-Substituted Spiro-/Ansa Cyclotriphosphazenes: Targeting Apoptosis via Heat Shock Protein Modulation in Breast and Colon Cancer Cells., PMID:40296721
Chronic lymphocytic leukemia: what clinical progress have we seen in the last five years?, PMID:40314223
Overexpression of Tgm2 in Chinese Hamster Ovary Cells Enhances Recombinant Monoclonal Antibody Expression and Promotes Cell Proliferation through Reduction of Apoptosis., PMID:40327404
HIV-Tat upregulates the expression of senescence biomarkers in CD4+ T-cells., PMID:40342418
Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403., PMID:40355425
Buzhong Yiqi decoction improves inflammation and oxidative damage in autoimmune thyroiditis by inhibiting apoptosis via the SIRT1-Mediated Nrf2/NF-κB axis., PMID:40360040
Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular Era., PMID:40361510
Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring., PMID:40377367
Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors., PMID:40379542
B cell receptor silencing reveals origin and dependencies of high-grade B cell lymphomas with MYC and BCL2 rearrangements., PMID:40402557
Genomic and Phenotypic Characterization of CHO 4BGD Cells with Quad Knockout and Overexpression of Two Housekeeping Genes That Allow for Metabolic Selection and Extended Fed-Batch Culturing., PMID:40422195
Revumenib for Relapsed or Refractory Acute Leukemia With a KMT2A Translocation., PMID:40437770
Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors., PMID:40442785
Hitting the Therapeutic Bullseye with Targeted Therapy for Patients with Chronic Lymphocytic Leukemia., PMID:40456120
Comparison of the Mutational Profile between BCL2- and BCL6-Rearrangement Positive Follicular Lymphoma., PMID:40482882
Comparative evaluation of a novel adhesive- Histoweld™ for immunohistochemistry: A non-inferiority study., PMID:40485404
Treatment of Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia., PMID:40494331
Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs., PMID:40507334
Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia., PMID:40515863
The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas., PMID:40524014
Tumor-Associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint Blockers., PMID:40530506
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study., PMID:40532125
Effects of Ganoderma spent substrate containing with polysaccharides and triterpenoids on the growth performance, antioxidant capacity and immunity level of chickens., PMID:40532998
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies., PMID:40534489
For research use only. Not for human or drug use.
